DOI:
10.1055/s-00000175
Arzneimittelforschung
LinksClose Window
References
Kamath AV, Wang J, Lee FY et al.
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Cancer Chemother Pharmacol 2008;
61: 365-376
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.